Frankfurt
03.10.25 | 15:29
6,050 Euro
-3,20 % -0,200
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | FDA verweigert Zulassung für Medikament von Fortress Biotech wegen Produktionsmängeln | 5 | Investing.com Deutsch | ||
| Do | Fortress Biotech stock faces setback as FDA issues CRL for CUTX-101 | 3 | Investing.com | ||
| Mi | Fortress Biotech stock plummets after FDA rejects Menkes disease drug | 13 | Investing.com | ||
| Mi | Fortress Biotech plunges as FDA rejects rare disease drug | 12 | Seeking Alpha | ||
| Mi | Fortress Biotech, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| Mi | Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing | 72 | GlobeNewswire (Europe) | Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange... ► Artikel lesen | |
| Mi | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 | 97 | GlobeNewswire (Europe) | MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S.... ► Artikel lesen | |
| FORTRESS BIOTECH INC PREF Aktie jetzt für 0€ handeln | |||||
| 21.08. | Fortress Biotech stock price target lowered to $17 at H.C. Wainwright | 26 | Investing.com | ||
| 14.08. | Fortress Biotech, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.08. | Fortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 382 | GlobeNewswire (Europe) | Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right... ► Artikel lesen | |
| 16.07. | Fortress Biotech, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 23.06. | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.06. | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.05. | Fortress Biotech, Inc.: Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics | 255 | GlobeNewswire (Europe) | MIAMI, May 30, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value... ► Artikel lesen | |
| 15.05. | Fortress Biotech, Inc.: Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | 400 | GlobeNewswire (Europe) | Emrosi commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint... ► Artikel lesen | |
| 16.04. | Fortress Biotech, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.03. | Fortress Biotech, Inc.: Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights | 134 | GlobeNewswire (Europe) | Emrosi approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary... ► Artikel lesen | |
| 17.03. | Fortress Biotech, Inc.: Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform | 227 | GlobeNewswire (Europe) | FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceutical company, today announced a strategic... ► Artikel lesen | |
| 27.01. | Fortress Biotech, Inc.: Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT | 250 | GlobeNewswire (Europe) | Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the... ► Artikel lesen | |
| 06.01. | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease | 431 | GlobeNewswire (Europe) | Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRYKER | 316,40 | +0,29 % | Dividendenbekanntmachungen (30.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1705 EUR ADVANCED FLOWER CAPITAL INC US00109K1051 0,15 USD 0,1279 EUR AG MORTGAGE INVESTMENT... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 516,40 | +0,12 % | EQS-News: Formycon AG: Formycon sichert US-Vermarktungsstart für Aflibercept-Biosimilar FYB203 durch Settlement-Vereinbarung mit Regeneron | EQS-News: Formycon AG
/ Schlagwort(e): Markteinführung/Vereinbarung
Formycon sichert US-Vermarktungsstart für Aflibercept-Biosimilar FYB203 durch Settlement-Vereinbarung mit Regeneron... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,800 | -0,46 % | Viking Therapeutics: Bald wieder im Rampenlicht? | Die Aktionäre von Viking Therapeutics mussten zuletzt einen herben Kursrückgang verkraften, während ein potenzieller Konkurrent für eine hohe Milliardenbewertung übernommen wurde. Dabei gilt Viking... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 16,895 | -0,56 % | Figma, Beam, Intellia: Cathie Wood setzt auf riskante (Bio-)Tech-Aktien | Die bekannte US-Investorin Cathie Wood blieb ihrer Linie auch im August 2025 treu und griff wieder einmal beherzt bei spekulativen Tech- und Biotech-Werten zu. Mit ihrem wichtigsten Fonds, dem ARK Innovation... ► Artikel lesen | |
| TEMPUS AI | 76,00 | -0,65 % | Why Tempus AI Stock Was Motoring Higher This Week | ||
| NUREXONE BIOLOGIC | 0,580 | -2,03 % | PTA-News: Aktien Global News: NurExone: Mit Rückenwind ins Zukunftsfeld der Exosomen-Medizin | DJ PTA-News: Aktien Global News: NurExone: Mit Rückenwind ins Zukunftsfeld der Exosomen-Medizin
Unternehmensmitteilung für den Kapitalmarkt
Aktien Global News: NurExone: Mit Rückenwind ins... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,294 | +2,91 % | PacBio Enters Carrier Screening Market With PureTarget Expansion | ||
| GINKGO BIOWORKS | 14,200 | +2,90 % | Ginkgo Bioworks Reports Second Quarter 2025 Financial Results | Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets
BOSTON, Aug. 7, 2025 /PRNewswire/ --... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 1,949 | -0,33 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SAN CARLOS, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,480 | -0,72 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,700 | -1,17 % | CytomX: Wie geht's hier jetzt weiter? | Die Immuntherapie gegen Krebs entwickelt sich stetig weiter, und CytomX Therapeutics gehört zu den Unternehmen, die mit innovativen Ansätzen neue Maßstäbe setzen wollen. Die sogenannte "Probody"-Technologie... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 3,950 | -0,50 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate... ► Artikel lesen | |
| BIOMEA FUSION | 2,155 | +1,17 % | Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | SAN CARLOS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or the "Company") (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that... ► Artikel lesen | |
| TERNS PHARMACEUTICALS | 6,800 | -3,55 % | Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) | FOSTER CITY, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule... ► Artikel lesen | |
| ADMA BIOLOGICS | 14,660 | +0,89 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen |
Das Unternehmen FORTRESS BIOTECH INC PREF kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,050 Euro und damit -3,20 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTRESS BIOTECH INC PREF finden Sie auf Wallstreet Online.